Anti-Inflammatory and Gut Microbiota Modulating Effects of Probiotic Lactobacillus paracasei MSMC39-1 on Dextran Sulfate Sodium-Induced Colitis in Rats.

Probiotics have been shown to possess several properties, depending on the strain. Some probiotics have important roles in preventing infection and balancing the immune system due to the interaction between the intestinal mucosa and cells in the immune system. This study aimed to examine the properties of three probiotic strains using the tumor necrosis factor-alpha (TNF-α) inhibition test in colorectal adenocarcinoma cells (Caco-2 cells). It was revealed that the viable cells and heat-killed cells of the probiotic L. paracasei strain MSMC39-1 dramatically suppressed TNF-α secretion in Caco-2 cells. The strongest strains were then chosen to treat rats with colitis induced by dextran sulfate sodium (DSS). Viable cells of the probiotic L. paracasei strain MSMC39-1 reduced aspartate transaminase and alanine transaminase in the serum and significantly inhibited TNF-α secretion in the colon and liver tissues. Treatment with the probiotic L. paracasei strain MSMC39-1 alleviated the colon and liver histopathology in DSS-induced colitis rats. Furthermore, supplementation with probiotic L. paracasei strain MSMC39-1 increased the genus Lactobacillus and boosted the other beneficial bacteria in the gut. Thus, the probiotic L. paracasei strain MSMC39-1 exhibited an anti-inflammation effect in the colon and modulated the gut microbiota.

Hepatoprotective Effect of Probiotic Lactic Acid Bacteria on Thioacetamide-Induced Liver Fibrosis in Rats.

Hepatic fibrosis is a reversible wound-healing response characterized by the accumulation of extracellular matrix. Probiotics have been used to prevent and treat various disorders. The aim of the present study was to investigate the hepatoprotective effects of probiotic lactic acid bacteria (mixture of Lactobacillus paracasei, Lactobacillus casei, and Weissella confusa) on thioacetamide (TAA)-induced liver fibrosis in rats. Thirty-five male Wistar rats were randomly divided into five groups: (1) control, (2) TAA, (3) TAA+probiotics, (4) TAA+silymarin, and (5) probiotics. Group 1 rats received a standard diet. In groups 2-4, fibrosis was induced by intraperitoneal injection of TAA (200 mg/kg BW) 3 times weekly for 8 consecutive weeks. Group 4 received TAA plus 100 mg/kg BW of silymarin 2 times weekly. Groups 3 and 5 were fed 109 CFU/mL viable microbial cells daily by gavage. The rats were sacrificed after 8 weeks of treatment. Liver tissues were collected immediately and processed for histopathological, lipid peroxidation, and Western blot analyses of TNF-α, TGF-ß1, and α-SMA. Blood serum was collected to measure liver enzymes. Rats in the TAA groups suffered from hepatic injury (increased serum enzyme levels, liver inflammation, and increased concentration of TNF-α, TGF-ß1, and α-SMA proteins) and extensive liver fibrosis. In contrast, TAA-treated rats receiving probiotics or silymarin had significantly lower serum enzyme levels, less inflammation, and less fibrosis. Liver damage was lower in the TAA+probiotics-treated group. Consumption of a mixture of probiotic lactic acid bacteria attenuates the development of liver fibrosis.